Advanced search
1 file | 974.13 KB

WRN promoter CpG island hypermethylation does not predict more favorable outcomes for patients with metastatic colorectal cancer treated with irinotecan-based therapy

(2016) CLINICAL CANCER RESEARCH. 22(18). p.4612-4622
Author
Organization
Keywords
MICROSATELLITE INSTABILITY, COMBINATION CHEMOTHERAPY, EPIGENETIC, INACTIVATION, METHYLATOR PHENOTYPE, RECQ HELICASES, BRAF MUTATION, DNA-REPAIR, CELL-LINE, GENE, ADENOCARCINOMAS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 974.13 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bosch, Linda JW, Yanxin Luo, Victoria V Lao, Petur Snaebjornsson, Geert Trooskens, Ilse Vlassenbroeck, Sandra Mongera, et al. 2016. “WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-based Therapy.” Clinical Cancer Research 22 (18): 4612–4622.
APA
Bosch, L. J., Luo, Y., Lao, V. V., Snaebjornsson, P., Trooskens, G., Vlassenbroeck, I., Mongera, S., et al. (2016). WRN promoter CpG island hypermethylation does not predict more favorable outcomes for patients with metastatic colorectal cancer treated with irinotecan-based therapy. CLINICAL CANCER RESEARCH, 22(18), 4612–4622.
Vancouver
1.
Bosch LJ, Luo Y, Lao VV, Snaebjornsson P, Trooskens G, Vlassenbroeck I, et al. WRN promoter CpG island hypermethylation does not predict more favorable outcomes for patients with metastatic colorectal cancer treated with irinotecan-based therapy. CLINICAL CANCER RESEARCH. 2016;22(18):4612–22.
MLA
Bosch, Linda JW, Yanxin Luo, Victoria V Lao, et al. “WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-based Therapy.” CLINICAL CANCER RESEARCH 22.18 (2016): 4612–4622. Print.
@article{8516960,
  author       = {Bosch, Linda JW and Luo, Yanxin and Lao, Victoria V and Snaebjornsson, Petur and Trooskens, Geert and Vlassenbroeck, Ilse and Mongera, Sandra and Tang, Weiliang and Welcsh, Piri and Herman, James G and Koopman, Miriam and Nagtegaal, Iris D and Punt, Cornelis JA and Van Criekinge, Wim and Meijer, Gerrit A and Monnat, , Raymond J, Jr and Carvalho, Beatriz and Grady, William M},
  issn         = {1078-0432},
  journal      = {CLINICAL CANCER RESEARCH},
  keyword      = {MICROSATELLITE INSTABILITY,COMBINATION CHEMOTHERAPY,EPIGENETIC,INACTIVATION,METHYLATOR PHENOTYPE,RECQ HELICASES,BRAF MUTATION,DNA-REPAIR,CELL-LINE,GENE,ADENOCARCINOMAS},
  language     = {eng},
  number       = {18},
  pages        = {4612--4622},
  title        = {WRN promoter CpG island hypermethylation does not predict more favorable outcomes for patients with metastatic colorectal cancer treated with irinotecan-based therapy},
  url          = {http://dx.doi.org/10.1158/1078-0432.CCR-15-2703},
  volume       = {22},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: